title: Combining immune checkpoint inhibitors for advanced melanoma: the key to optimizing treatment outcomes?
authors.affiliation: UCL Medical School, Gower Street, London, UK.
authors.forename: Sarah
authors.initials: S
authors.lastname: Freeston
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018816:Genes, cdc / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents
keywords: CTLA-4; PD-1; immunotherapy; ipilimumab; melanoma; nivolumab